Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
Optimi Health completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial. The shipment included both psilocybin biomass and finished 5mg capsules, manufactured at Optimi's GMP facility in Princeton, British Columbia, under export authorization from Health Canada and import authorization from the UK Home Office.
Key figures
- Drug Name
- psilocybin
- Phase Of Trial
- Phase 2
- Capsule strength
- 5mg
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.